Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

BACKGROUND: The use of checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab) has revolutionised the treatment of metastatic melanoma. However still more than the half the patients do not respond to single-agent immunotherapy. This has led to the development of combining these agents in an att...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalgleish, Angus G., Mudan, Satvinder, Fusi, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092867/
https://www.ncbi.nlm.nih.gov/pubmed/30107850
http://dx.doi.org/10.1186/s12967-018-1602-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092867/
https://www.ncbi.nlm.nih.gov/pubmed/30107850
http://dx.doi.org/10.1186/s12967-018-1602-8

Ejemplares similares